Stockreport

Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight [Globe and Mail, The (Toronto, Canada)]

Eli Lilly and Company  (LLY) 
Last eli lilly and company earnings: 4/23 06:25 am Check Earnings Report
US:NYSE Investor Relations: investor.lilly.com
PDF Retatrutide, a subcutaneous triple hormone receptor agonist in phase 3 trials, could be a game changer. If both drugs succeed, Eli Lilly could dominate the anti-obesi [Read more]